September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Efficacy of Ranibizumab Therapy with Aflibercept in Patients with Diabetic Macular Edema
Author Affiliations & Notes
  • Leonardo Pinheiro Teixeira
    Retina - Einhorn Research Center, Instituto de Olhos de Goiânia, Teresina, Brazil
  • Eduardo Dalia
    Retina - Einhorn Research Center, Instituto de Olhos de Goiânia, Teresina, Brazil
  • Luana Campos
    Retina - Einhorn Research Center, Instituto de Olhos de Goiânia, Teresina, Brazil
  • Mayara Martins Abrahao
    Retina - Einhorn Research Center, Instituto de Olhos de Goiânia, Teresina, Brazil
  • Joao J Nassaralla
    Retina - Einhorn Research Center, Instituto de Olhos de Goiânia, Teresina, Brazil
  • Footnotes
    Commercial Relationships   Leonardo Pinheiro Teixeira, None; Eduardo Dalia, None; Luana Campos, None; Mayara Martins Abrahao, None; Joao Nassaralla, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5041. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Leonardo Pinheiro Teixeira, Eduardo Dalia, Luana Campos, Mayara Martins Abrahao, Joao J Nassaralla; Efficacy of Ranibizumab Therapy with Aflibercept in Patients with Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5041.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Compare the efficacy of treatment of diabetic macular edema (DME) using Ranibizumab (Lucenti®), Aflibercept (Eylea®) and Aflibercept (Eylea®) plus Ranibizumab (Lucentis®)

Methods : Interventions were performed with intravitreal injections in patients with formal indications of diabetic macular edema treatment previously evaluated with complete eye exam at ‘Instituto de Olhos de Goiânia’ from October 2015 to May 2016. The patients were divided into four groups:
- In the first group were made 3 Intravitreal applications of Ranibizumab 0.1ml, with one application per month and monitoring with Optical Coherence Tomography on days 1, 3, 5, 10 and 30 subsequent to application.
- In the second group were performed 3 intravitreal applications of Aflibercept 0.1 ml, with one application per month followed by monitoring with Optical Coherence Tomography on days 1, 3, 5, 10 and 30 subsequent.
- In the third group were realized 2 applications of Ranibizumab 0.1 ml interspersed with one application of Aflibercept 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography on days 1, 3, 5, 10 and 30.
- In the fourth group were made 2 applications of Aflibercept 0,1 ml interspersed with one application of Ranibizumab 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography on days 1, 3, 5, 10 and 30.

Results : It was observed a significant reduction of diabetic macular edema in all groups, and this occurred mainly in the early days of application and the first two doses. The group treated with aflibercept isolated and the group treated with ranibizumab isolated had similarity in reducing macular edema, while the groups treated with interspersed doses were similar and had a better efficacy compared the effectiveness of two other groups mentioned.

Conclusions : The treatment of diabetic macular edema interspersed with doses of different substances used for the same purpose have had a better efficacy than treatment with these substances isolated.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×